English | 繁體

Search in the results

UM

Browse/Search Results:  1-1 of 1 Help

Selected(0)Clear Items/Page:    Sort:
Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis Journal article
Wu, Hao Xiang, Pan, Yi Qian, He, Ye, Wang, Zi Xian, Guan, Wen Long, Chen, Yan Xing, Yao, Yi Chen, Shao, Ning Yi, Xu, Rui Hua, Wang, Feng. Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis[J]. Journal of Clinical Oncology, 2023, 41(9), 1735-1746.
Authors:  Wu, Hao Xiang;  Pan, Yi Qian;  He, Ye;  Wang, Zi Xian;  Guan, Wen Long; et al.
Favorite | TC[WOS]:30 TC[Scopus]:32  IF:42.1/37.4 | Submit date：2023/04/03
Pembrolizumab  Placebo  Camrelizumab  Nivolumab  Survival  Efficacy  Therapy  Safety  Chemo